会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 61. 发明授权
    • Driving game board apparatus
    • 驾驶游戏机设备
    • US4341388A
    • 1982-07-27
    • US225872
    • 1981-01-19
    • John Carter
    • John Carter
    • A63F3/00
    • A63F3/00088A63F3/00006
    • Driving game apparatus including a game board with an endless two-way course thereon extending around a central area and having inner and outer lanes. A plurality of individual home areas are arranged around the central area and each has an identification different from the others. A plurality of playing pieces simulating vehicles are used, there being one playing piece for each home area and having the identification of the latter. An in-out pathway extends between each home area and the roadway course. A plurality of inward and outward detour roads extend from the central area to the roadway course, and there are a plurality of indicator sections on the pathways, the roadway course and the detour roads, and a plurality of individual instruction cards, these sections and cards containing different driving instructions, penalties and awards. The game is played with chance number indicating means, such as dice.
    • 驾驶游戏装置包括游戏板,该游戏板具有围绕中心区域延伸并且具有内部和外部车道的无限双向路线。 多个单独的家庭区域围绕中心区域布置,并且每个家庭区域具有与其他区域不同的标识。 使用模拟车辆的多个玩具,每个家庭区域都有一个玩具,并且具有后者的识别。 在每个家庭区域和道路路线之间延伸一个内部通道。 多个向内和向外的绕行道路从中心区域延伸到道路路线,路径上的多个指示器部分,道路路线和绕行道路以及多个单独的指示卡,这些部分和卡片 包含不同的驾驶说明,罚款和奖励。 该游戏使用机会数字表示手段,如骰子。
    • 68. 发明申请
    • Electro-therapy method
    • 电疗法
    • US20080033492A1
    • 2008-02-07
    • US11539551
    • 2006-10-06
    • Bradford SiffJohn Carter
    • Bradford SiffJohn Carter
    • A61N1/34
    • A61N1/36021A61N1/05A61N1/36017
    • A method of introducing therapeutic electrical energy to the body tissues in a treatment site beneath the epidermis of a patient is disclosed. The method requires an electro-therapy apparatus with a signal generator and at least one percutaneous electrode array. The percutaneous electrode array is placed on a portion of the patient's body above the treatment site, and a therapeutic signal is passed through the array. The method may also include the use of a non-invasive electrode pad in addition to the array as part of the electro-therapy apparatus. The method may also include monitoring and controlling the voltage associated with the patient's use of the electro-therapy apparatus.
    • 公开了一种将治疗电能引入患者表皮下的治疗部位的身体组织的方法。 该方法需要具有信号发生器和至少一个经皮电极阵列的电疗设备。 经皮电极阵列放置在治疗部位上方的患者身体的一部分上,治疗信号通过阵列。 除了作为电疗设备的一部分的阵列之外,该方法还可以包括使用非侵入性电极焊盘。 该方法还可以包括监测和控制与患者使用电疗装置相关联的电压。
    • 70. 发明申请
    • Novel formulation of pyridoxal-5'-phosphate and method of preparation
    • 吡哆醛-5'-磷酸的新配方及其制备方法
    • US20070243249A1
    • 2007-10-18
    • US11288971
    • 2005-11-28
    • Albert FriesenJohn Carter
    • Albert FriesenJohn Carter
    • A61K9/20A61K31/675A61K9/28
    • A61K31/675A61K9/1635A61K9/1652A61K9/2009A61K9/2054A61K9/2077A61K9/2846A61K9/2866A61K9/2886
    • A pyridoxal-5′-phosphate pharmaceutical formulation suitable for oral administration is provided comprising a dissolution profile, when measured in a standard dissolution apparatus, according to the United States Pharmacopoeia dissolution test, at 37° C. in a 0.05M phosphate buffered solution having a pH of 6.8 at 75 rpm, as follows: (a) greater than about 30% at 15 minutes, (b) greater than about 85% at 30 minutes, (c), greater than about 90% at 45 minutes, or (d) greater than about 95% at 60 minutes. Additionally, in vivo oral intake of between 15 and 60 mg/kg of a pyridoxal-5′-phosphate pharmaceutical formulation can produce a maximum plasma level (Cmax) of between about 1 mg/L and 8 mg/L. A pharmaceutical formulation provided comprises (a) a core, wherein said core comprises pyridoxal-5′-phosphate or a pharmaceutically acceptable salt thereof; (b) a sub-coat surrounding the core; and (c) an enteric coat surrounding the sub-coat.
    • 提供了适合于口服给药的吡哆醛-5'-磷酸药物制剂,其包含在标准溶出装置中根据美国药典溶出度测试在37℃下在0.05M磷酸盐缓冲溶液中测定的溶出曲线, 在75rpm下的pH为6.8,如下:(a)在15分钟时大于约30%,(b)在30分钟时大于约85%,(c),在45分钟时大于约90%,或( d)在60分钟时大于约95%。 此外,15至60mg / kg吡哆醛-5'-磷酸药物制剂的体内口服摄入量可以产生约1mg / L至8的最大血浆水平(C max max) mg / L。 提供的药物制剂包含(a)核心,其中所述核心包含吡哆醛-5'-磷酸酯或其药学上可接受的盐; (b)围绕该核心的副衣服; 和(c)围绕小衣的肠衣。